Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE
Authors:
Open Access
- 16 January 2018
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 29 (3) , 766-771
Abstract
The impressive progress recently observed in adult cancers through the introduction of new drugs has not yet been translated to adolescents 12–17 years of age [defined according to the International Conference on Harmonization (ICH) E11]. The current drug development landscape separates adult and paediatric drug development (Table 1). Adolescents are grouped with children, leading to a mismatch with a lack of trials for adolescents with relapsed cancer and delayed access to new, effective drugs already available for adults.Keywords
Funding Information
- Oak Foundation (OCay-04-169, LO1605, 1413)
This publication has 28 references indexed in Scilit:
- Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 studyThe Lancet Oncology, 2013
- A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic MalignanciesClinical Cancer Research, 2012
- Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group StudyClinical Cancer Research, 2011
- Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in ChildrenClinical Cancer Research, 2011
- Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid TumorsClinical Cancer Research, 2011
- Clinical Pharmacology in the Adolescent Oncology PatientJournal of Clinical Oncology, 2010
- Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt LeukemiaJournal of Clinical Oncology, 2010
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyThe Lancet Oncology, 2010
- European Union Ethical Considerations for Clinical Trials on Medicinal Products Conducted with the Paediatric PopulationEuropean Journal of Health Law, 2008
- Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct EfficiencyJournal of Clinical Oncology, 2005